Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant
Launched by ESPERION THERAPEUTICS, INC. · Dec 7, 2016
Trial Information
Current as of June 07, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Require lipid-modifying therapy for primary or secondary prevention of cardiovascular disease
- • Fasting LDL-C ≥130 mg/dL for primary prevention or LDL-C ≥100 mg/dL for secondary prevention (history of HeFH and/or ASCVD)
- • Be statin-intolerant (unable to tolerate 2 or more statins)
- Exclusion Criteria:
- • Total fasting triglyceride ≥500 mg/dL
- • Renal dysfunction or nephrotic syndrome or history of nephritis
- • Body Mass Index (BMI) ≥50 kg/m2
- • Significant cardiovascular disease or cardiovascular event in the past 3 months
About Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc. is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with cardiovascular diseases. With a focus on addressing unmet medical needs, Esperion specializes in lipid management and the reduction of cardiovascular risk, leveraging its expertise in drug development to bring novel treatments to market. The company's commitment to advancing science is reflected in its robust pipeline of therapies aimed at improving patient outcomes and enhancing quality of life. Through strategic collaborations and a patient-centered approach, Esperion strives to redefine the future of cardiovascular care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Atlanta, Georgia, United States
San Antonio, Texas, United States
Iowa City, Iowa, United States
Columbus, Ohio, United States
Knoxville, Tennessee, United States
Houston, Texas, United States
Torrance, California, United States
Orlando, Florida, United States
Greensboro, North Carolina, United States
Memphis, Tennessee, United States
Anaheim, California, United States
Long Beach, California, United States
Lincoln, Nebraska, United States
Santa Ana, California, United States
Oklahoma City, Oklahoma, United States
Sacramento, California, United States
West Palm Beach, Florida, United States
Daytona Beach, Florida, United States
Amarillo, Texas, United States
Tupelo, Mississippi, United States
Fort Lauderdale, Florida, United States
Hampton, Virginia, United States
Evanston, Illinois, United States
Savannah, Georgia, United States
Toronto, , Canada
Evansville, Indiana, United States
Marion, Ohio, United States
Waterloo, Iowa, United States
Beaver, Pennsylvania, United States
London, , Canada
Newmarket, , Canada
Anderson, South Carolina, United States
Slidell, Louisiana, United States
Meridian, Idaho, United States
Binghamton, New York, United States
Jackson, Tennessee, United States
Endwell, New York, United States
Hamden, Connecticut, United States
Ventura, California, United States
Monroe, Louisiana, United States
Langhorne, Pennsylvania, United States
Gilbert, Arizona, United States
Maumee, Ohio, United States
Morganton, North Carolina, United States
Cumberland, Rhode Island, United States
Somerset, New Jersey, United States
Kenosha, Wisconsin, United States
New Windsor, New York, United States
Pointe Claire, , Canada
Summerville, South Carolina, United States
Clinton, Utah, United States
Chicoutimi, , Canada
Montréal, , Canada
Gatineau, , Canada
Mount Airy, North Carolina, United States
Miami, Florida, United States
Miami, Florida, United States
Dallas, Texas, United States
Dallas, Texas, United States
Brossard, , Canada
Longueuil, , Canada
Mirabel, , Canada
Oakville, , Canada
Peterborough, , Canada
Saint Jérôme, , Canada
Sarnia, , Canada
Victoriaville, , Canada
Patients applied
Trial Officials
Ron Haberman, MD
Study Director
Esperion Therapeutics, Inc.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials